The possible reason is that the inhibition of caspase-11 by wedelolactone involves changes in complex pathways such as IkappaK/IkappaB/nuclear factor-κB (NF-κB), which may affect other phenotypes of asthma [53]. This evidence concerns the gene NFKB1 and asthma.